Metabomed will be financed by a syndicate led by MS Ventures together with Boehringer Ingelheim Venture Fund, Pontifax LLC and the Technion Research and Development Foundation Metabomed brings together three world-leading researchers to focus on drug discovery in the field of novel targets in cancer metabolism.
Read More
NEWS
EVENTS
Publications
NEWS
-
Metabomed joins Merck Serono Israel Bioincubator
-
Cancer Metabolism Company Metabomed Completes $18 Million Series A Financing
Existing Investors MS Ventures, Boehringer Ingelheim Venture Fund, Pontifax LLC and the Technion Research and Development Foundation are joined by Pfizer Inc. and Arkin Holdings Simone Botti, Head of MS Ventures Israel BioIncubator Fund, will join the company as full time CEO.
Read More
In The Press
-
Metabomed: A New Venture in Israel’s Start-Up Ecosystem that Tackles Cancer’s Altered Metabolism – A Chat with Simone Botti, Former Head of Merck Ventures’ Israel BioIncubator and CEO of Metabomed
wuxiapptec, 12 Sep, 2016 | READ MORE -
Cancer Metabolism Company Metabomed Completes $18 Million Series A Financing
fierce biotech, 7 Apr, 2016 | READ MORE -
Cancer metabolism co Metabomed raises $18m
globes, 4 Apr, 2016 | READ MORE
Publications
-
Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase
Nature | READ MORE -
Predicting selective drug targets in cancer through metabolic networks
Mol Syst Biol | READ MORE -
Predicting Cancer-Specific Vulnerability via Data-Driven Detection of Synthetic Lethality
CELL | READ MORE -
Acetyl-CoA Synthetase 2 Promotes Acetate Utilization and Maintains Cancer Cell Growth under Metabolic Stress
CANCER CELL | READ MORE -
Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis
Nature Cell Biology | READ MORE